The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$92,922 거래량
$92,922 거래량
2026.12.31
$92,922 거래량
$92,922 거래량
2026.12.31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
마켓 개설일: May 4, 2026, 10:39 AM ET
거래량
$92,922종료일
2026.12.31마켓 개설일
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
거래량
$92,922종료일
2026.12.31마켓 개설일
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트
외부 링크에 주의하세요.
외부 링크에 주의하세요.
자주 묻는 질문